Exoxemis Products for the Prevention and Treatment of Serious Infectious Dieseases
Technology Indications Collaborations Company Publications Contact
 
>

Technology

Myeloperoxidase (MPO) and eosinophil peroxidase (EPO) enzymes work to preferentially kill a broad range of pathogens through a unique mechanism of action unlikely to induce resistance. more >>

Microbiological infection caused by bacteria, viruses, fungi, and prions is an important concern in a range of healthcare sectors affecting human health and well-being. Safe and effective microbicidal products are especially critical today, when antimicrobial resistance and the potential for the rapid spread of pathogens have become public-health issues in countries throughout the world.

For 20 years, Exoxemis, Inc. has been the leader in the development of broad-spectrum haloperoxidase-based products for use in high-value product areas, including a biological entity for use in high morbidity/mortality applications. We are committed to integrating our technology with the intellectual, financial, and commercial strengths of prospective partners to develop innovative products and long-term relationships.

Surgical Infection News

Are new threats emerging beyond MRSA?
An article appearing recently in The New York Times discusses gram-negative bacteria, such as Acinetobacter baumannii, that are beginning to exhibit antimicrobial resistance in hospital and community settings.
Learn more >>

 
>

Licensing

We leverage our proprietary know-how and technology platform through product licensing and collaborations in areas of unmet clinical need. more >>